Anticholinergic drugs versus placebo for overactive bladder syndrome in adults - Test2 - elhamkhani - TriplyDB

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

http://www.wikidata.org/entity/Q24243870

about

Lifestyle interventions for the treatment of urinary incontinence in adults Anticholinergics for urinary symptoms in multiple sclerosis Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women Pelvic floor muscle training versus other active treatments for urinary incontinence in women Oestrogen therapy for urinary incontinence in post-menopausal women Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women Urodynamic studies for management of urinary incontinence in children and adults Urodynamic studies for management of urinary incontinence in children and adults Which anticholinergic drug for overactive bladder symptoms in adults Botulinum toxin injections for adults with overactive bladder syndrome Comparisons of approaches to pelvic floor muscle training for urinary incontinence in women Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women Lifestyle interventions for the treatment of urinary incontinence in adults Oestrogen therapy for urinary incontinence in post-menopausal women Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women Anticholinergics for urinary symptoms in multiple sclerosis Anticholinergic drugs versus other medications for overactive bladder syndrome in adults Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults Botulinum toxin injections for adults with overactive bladder syndrome Absorbent products for light urinary incontinence in women An update on the use of transdermal oxybutynin in the management of overactive bladder disorder The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder.A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.Efficacy and safety of Baweidihuang-wan in women with overactive bladder: a randomized, double blind, placebo controlled trial Urodynamic investigations for management of urinary incontinence in adults.Postmenopausal overactive bladder How effective are common medications: a perspective based on meta-analyses of major drugs.Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.Randomized, double-blind, placebo-controlled trial of polyethylene glycol (MiraLAX®) for urinary urge symptoms.A phase II dose-ranging study of mirabegron in patients with overactive bladder Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin.In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder.Update on tolterodine extended-release for treatment of overactive bladder

P2860

Q24187247-01C3D474-AC34-4679-A806-87E12D7EB4E5 Q24187386-DBAEFFF2-C60D-4C7F-8470-2483BAA11EB9 Q24187989-63D19B06-A903-40EA-AB0B-A5AA581FDC8B Q24194428-49659DE2-21D2-4E37-9519-369385110EB5 Q24198065-658AA293-CF6A-402D-8832-14EE284E76E3 Q24202075-F312A6FC-BBC5-46D1-BCF5-698FEE2A0519 Q24202394-94312BDD-9D39-4F1A-A966-BBDCF796F971 Q24202506-6326EC9D-BDC0-439B-9566-FBBFFD961738 Q24202865-14778429-2411-4B08-A1B6-F8424378B89A Q24203846-DA1EE3CB-49F2-48B4-9BD9-E4C65C4E9711 Q24203880-C4AE270E-A363-423F-8505-030A1335258E Q24204043-CFF951C1-D0DD-4AFA-8CAC-D67A991AFD76 Q24234222-12A9C836-0E99-4FF9-8D2D-0402FDB96AFD Q24235631-95243D9B-FFCE-41DA-933B-A97927FABAA4 Q24235836-BC6497DD-B105-4B3B-9ACD-6812E55D4097 Q24240302-4589CE25-8EDB-4E91-A7DC-276A7587F666 Q24240940-93791477-83CD-4423-92FB-C24186D7A42A Q24241666-42C32E2E-0647-4248-ABAA-90C5D91750BD Q24243527-B61B4CF6-68AE-4FE2-8683-02F691C1CA5E Q24243956-7CCF2A5B-2246-48FF-8001-A9B108BE0040 Q24243963-8A2EDCAE-FB00-4E5D-9802-F58F262CBD12 Q24245170-AF437FCE-57E3-45DF-9146-BAA8F5FEC03B Q26749105-EE2D4BAE-F40A-47A9-AC58-64DA51C1A55C Q26770419-C46EC52E-6398-436B-B99B-D99CC9E115E6 Q26851170-A2598870-8B13-4A7A-A976-4DAFAF35EF85 Q28742444-C2A2127C-430F-43C2-8B31-6069AC992927 Q30906698-235E0413-5E47-4FA9-A60D-AE02A9C2AD79 Q33485538-D24C9F0D-9DD2-4657-8802-A739EA59C853 Q33605919-70265E32-1CD6-49F9-804F-2EF6DF1074CA Q33696642-73AE4774-79D4-487F-8AD7-F29D3800BCCB Q34415046-6082561A-C874-41B5-8180-0766519BBCD0 Q34758230-81E0D7D9-F67C-42D1-9FAD-9167BB8C6778 Q35157329-2CE827AD-0504-4853-B3E8-E531F4264DCD Q35797656-C93026E5-8404-4C2F-B87B-EE612A4B8370 Q36528534-2CFFB672-5FA2-4875-8D7E-15E702ECCBAC Q36810583-144AAD14-9C78-4F8A-A0E7-3DE6B20DE5D2 Q37100337-6AAE2B83-9B8C-4561-952A-0F25813DFC1E Q37192944-CAD4D1A5-46C6-40E8-B62C-4DF5935775D7 Q37230811-BDB12D03-662A-480F-84AC-F76F5446625D Q37283585-8581C846-2A1F-4BFF-B249-D87A17AB1B99

P2860

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

http://www.wikidata.org/entity/Q24243870

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@ast

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@en

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@en-gb

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@nl

type

label

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@ast

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@en

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@en-gb

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@nl

prefLabel

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@ast

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@en

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@en-gb

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@nl

P1433

Q24243870-D34D8E61-93F0-4977-B4E7-20B9683E360D

P1476

Q24243870-45D7BCFA-C30D-46B6-868D-2C8F26CD19D7

P2093

Q24243870-51ADA44E-BC3A-425A-A6FD-2E629BA8DA8F

Q24243870-70CF94DD-5465-4778-832E-1AEBE2D2B5F1

Q24243870-B9A3909C-3E4D-4010-8961-87D6A0D0D76B

Q24243870-C03E7322-DE8A-40C6-9D8C-069E76D19B70

Q24243870-C71F939D-F012-4A49-A661-FEFD233DB8CC

P2860

Q24243870-047B094F-2347-4B1A-967C-0950A6038D8B

Q24243870-075F3092-AC09-46E3-8AE8-BCC33FC6E7BA

Q24243870-088CD04D-6FFD-4FA9-84BC-2C3060DA41CB

Q24243870-0D379CED-BD02-41C0-B756-62A56FADF729

Q24243870-0E2E1354-70D4-4BF2-BC83-87C407C9B275

Q24243870-10C0261A-C8A3-4577-BDFD-97C54EB7BCC8

Q24243870-1ADD96F7-39A5-4EB8-A067-B6A970627D5E

Q24243870-1BE87107-1D04-4CB8-9C35-AE23E93382C5

Q24243870-1DBAE674-8F01-476D-B272-4E10216A0ACC

Q24243870-2CF32D4B-73AE-43AA-8E95-70A8AB738C09

P31

Q24243870-1FF57302-1750-4825-9E22-4E336729966B

Q24243870-34e915fd-dfe4-4b91-8b8a-d2512c4c89ed

P356

Q24243870-DD919F1A-E9BB-4922-B1ED-76FE423C4E7C

P577

Q24243870-10E2BF44-F834-4C42-8CDE-D5E091B5E075

P698

Q24243870-B1555F85-44A8-4E1A-9DC3-50CFBD78474B

P921

Q24243870-142FE2F3-8D56-4299-909B-0441FBC170C0

P356

14651858.CD003781.PUB2

P1433

Cochrane Database of Systematic Reviews

P1476

Anticholinergic drugs versus placebo for overactive bladder syndrome in adults

@en

P2093

G Peter Herbison

http://www.w3.org/2001/XMLSchema#string

Gaye Ellis

http://www.w3.org/2001/XMLSchema#string

Ghulam Nabi

http://www.w3.org/2001/XMLSchema#string

Jean Hay-Smith

http://www.w3.org/2001/XMLSchema#string

June D Cody

http://www.w3.org/2001/XMLSchema#string

P2860

Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults

Which anticholinergic drug for overactive bladder symptoms in adults

Anticholinergic drugs versus other medications for overactive bladder syndrome in adults

Bladder training for urinary incontinence in adults

Urinary, faecal and sexual dysfunction in patients with multiple sclerosis

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.

Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens.

Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women.

What are pragmatic trials?

P31

scholarly article

P356

10.1002/14651858.CD003781.PUB2

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17054185

http://www.w3.org/2001/XMLSchema#string

P921